Summary
Coagulation parameters, platelet aggregation, and thromboxane production as well as metabolic parameters were measured in 31 diabetic patients, 12 without and 19 with clinically manifest late complications, and in 14 healthy control subjects. Spontaneous in vitro aggregation as well as ADP, collagen, and arachidonic acid induced aggregation were higher in both groups of diabetic patients, without an increase in thromboxane B2 production.
In diabetic patients with late complications an increase in fibrinogen, fibrinogen cyanogen bromide peptide, factor VIII related antigen, C1-esterase inhibitor, and antithrombin III was observed in comparison to healthy subjects. Fibrinogen, C1-esterase inhibitor, and factor VIII related antigen were already elevated in diabetic patients without clinically manifest late vascular complications.
No strict correlations were found between serum glucose, glycosylated hemoglobin, and glycosylated albumin, on the one hand, and coagulation promoting or inhibiting factors, aggregation or thromboxane B2 production, on the other, in either control or diabetic subjects. Also no correlations existed between the coagulation parameters and the aggregation results.
In vitro incubation of pooled normal plasma with different glucose concentrations had no influence on the methods by which the coagulation parameters were measured.
These data indicate that rather early in the diabetic state many changes take place in different phase of the thrombostatic process, all resulting in an increased hemostatic diathesis.
Article PDF
Similar content being viewed by others
Abbreviations
- AA:
-
Arachidonic acid
- ADP:
-
Adenosine 5′-diphosphate
- AT III:
-
Antithrombin III
- C1-INA:
-
C1 esterase inhibitor
- D(+):
-
With D(−)=without late diabetic complications
- F-CB 3:
-
Fibrinogen cyanogen bromide peptide
- FI:
-
fibrinogen
- F VIII RAg:
-
Factor VIII related antigen
- HbA1 :
-
Glycosylated hemoglobin
- imm.:
-
Immunological
- PRP:
-
Platelet-rich plasma
- TXB2 :
-
Thromboxane B2
References
Abraham EC, Huff TA, Cope ND, Wilseon JB, Bransome ED, Huisman THJ (1978) Determination of the glycosylated hemoglobin (HbA1) with a new microcolumn procedure. Diabetes 27:931–937
Blombäck M, Blombäck B (1974) The assay of antithrombin III using a synthetic chromogenic substrate for thrombin. Thromb Res 5:621–632
Borkenstein MH, Muntean WE (1982) Elevated factor VIII activity and factor VIII-related antigen in diabetic children without vascular disease. Diabetes 31:1006–1009
Burrows AW, Chavin SI (1978) Plasma thromboglobulin concentrations in diabetes mellitus. Lancet I:235–237
Casparie AF (1981) Plasma beta-thromboglobulin in diabetics with and without microangiopathic complications. Diabetologia 21:160–161
Cederholm-Williams SA, Dornan TL, Turner RC (1981) The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man. Eur J Clin Invest 11:133–138
Cederholm-Williams SA, Haitus B, Dorman TL, Turner RC (1983) Abnormal release of vascular plasminogen activator associated with diabetic microangiopathy. In: Jespersen J, Kluft C, Korsgaard O (eds) Clinical aspects of fibrinolysis and thrombolysis. South Jutland University Press, Esbjerg, Denmark, pp 322–335
Christe M, Fritschi J, Lämmle B, Tran TH, Marbet GA, Berger W, Duckert F (1984) Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 52:138–143
Christe M, Gattlen P, Fritschi J, Lämmle B, Berger W, Marbet GA, Duckert F (1984) The contact phase of blood coagulation in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 52:221–223
Clauss A (1957) Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 17:237
Dolhofer R, Wieland OH (1980) Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 29:417–422
Elder GE, Mayne EE, Daly JG, Kennedy AL, Hadden DR, Montgomery DAD, Weaver JA (1980) Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. Haemostasis 9:288–296
Ewald U, Kobbah M, Vessby B, Tuvemo T (1983) Increased platelet aggregability in diabetic children: relation to serum lipid and fatty acid composition. Diabetologia 25:382–385
Fagerhol MK, Abildgaard U (1970) Immunological studies of human antithrombin III. Scand J Haemat 7:10–17
Friedrich H (1970) Normographische Bestimmung und Beurteilung von Regressions-und Korrelationskoeffizienten. Biometrische Zeitschr 12:163–187
Fritschi J, Christe M, Lämmle B, Marbet GA, Berger W, Duckert F (1984) Platelet aggregation, β-thromboglobulin and platelet factor 4 in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 52:236–239
Giugliano D, Misso L, Tirelli A, Coppola L, Di Ponto P, Torella R (1982) Platelet aggregation after strict metabolic control using the artificial pancreas. Diabetologia 23:545
Gollwitzer R (1977) Immunological assay for a carboxyterminal peptide of the fibrinogen A-chain in normal and pathological human sera. Thromb Res 11:859–863
Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday WH (1979) Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 63:1060–1065
Jackson CA, Greaves M, Boulton AJM, Ward JD, Preston FE (1984) Near-normal glycaemic control does not correct abnormal platelet reactivity in diabetes mellitus. Clin Sci 67:551–555
Jones DB, Carter RD, Haitas B, Mann JI (1983) Low phospholipid arachidonic acid values in diabetic platelets. Br Med J 286:173–175
Kalofoutis A, Lekakis J (1981) Changes of platelet phospholipids in diabetes mellitus. Diabetologia 21:540–543
Kubisz P, Arabi A, Holan J, Cronberg S (1984) Investigations on platelet function in diabetes mellitus. Haemostasis 14:347–353
Landgraf-Leurs MMC, Loy A, Cristea C, Weber PC, Siess W, Herberg LL, Landgraf R (1981) Aggregation and thromboxane B2 formation in platelets and vascular prostacyclin production from genetically obese rats. Prostaglandins 22:521–535
Landgraf-Leurs MMC, Landgraf R, Loy A, Weber PC, Herberg LL (1982) Aggregation and thromboxane formation by platelets and vascular prostacyclin production from BB rats. An animal model for type 1 diabetes. Prostaglandins 24:35–46
Laurell CB (1965) Antigen-antibody crossed electrophoresis. Anal Biochem 10:358
Laurell CB (1966) Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 15:45–52
Levin RD, Kwaan HC, Dobbie JG, Fetkenhour CL, Traisman HS, Kramer C (1982) Studies of retinopathy and the plasma cofactor of platelet hyperaggregation in type 1 (insulin dependent) diabetic children. Diabetologia 22:445–449
Lowe GDO, Lowe JM, Drummond MM, Reith S, Belch JJF, Kesson CM, Wylie A, Foulds WS, Forbes CD, Mac-Cuish AC, and Manderson WG (1980) Blood viscosity in young male diabetics with and without retinopathy. Diabetologia 18:359–363
Lütjens A, te Velde AA, v d Veen EA, v d Meer J (1985) Glycosylation of human fibrinogen in vivo. Diabetologia 28:87–89
Meyer-Bertenrath JG (1980) Blutgerinnung und Fibrinolyse. 5th edn. Dtsch Ärzte-Verlag, Köln-Lövenich
Muntean WE, Borkenstein MH, Haas J (1985) Elevation of factor VIII coagulant activity over factor VIII coagulant antigen in diabetic children without vascular disease. A sign of activation of the factor VIII coagulant moiety during poor diabetes control. Diabetes 34:140–144
Murphy RP, Patz A (1983) The natural history and management of nonproliferative diabetic retinopathy. In: Little HL, Jack RL, Patz A, Forsham PH (eds) Diabetic retinopathy. Thieme, Stuttgart-New York, pp 225–241
Ney KA, Pasqua JJ, Colley KJ, Guthrow CE, Pizzo SV (1985) In vitro preparation of nonenzymatically glycosylated human transferrin, α2-macroglobulin, and fibrinogen with preservation of function. Diabetes 34:462–470
Paisey RB, Harkness J, Hartog M, Chadwick T (1980) The effect of improvement in diabetic control on plasma and whole blood viscosity. Diabetologia 19:345–349
Petersen HD, Gormsen J (1978) Platelet aggregation in diabetes mellitus. Acta Med Scand 203:125–130
Porta M (1982) Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue. Diabetologia 23:452–455
Porta M, Hilgard P, Kohner EM (1980) Platelet shape change abnormalities in diabetic retinopathy. Diabetologia 18:217–221
Porta M, Townsend C, Clover GM, Nanson M, Alderson AR, McCraw A, Kohner EM (1981) Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20:597–601
Schmidt FH (1961) Die enzymatische Bestimmung von Glucose und Fructose nebeneinander. Klin Wochenschr 39:1244–1247
Schramm W (1984) C1-Esterase Inhibitor. C1 Inactivator. In: Bergmeyer HU, Bergmeyer J, Graßl M (eds) Methods of enzymatic analysis. Verlag Chemie, Weinheim Deerfield Beach/Florida-Basel, pp 461–466
Siess W, Roth P, Weber PC (1981) Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin — a critical evaluation. Thromb Haemostas 45:204–207
Svendsen L, Stocker K (1977) Determination of protease activities with specifically constructed peptide-p-nitro-anilide derivates. In: Witt I (ed) New methods for the analysis of coagulation using chromogenic substrates. de Gruyter, Berlin-New York, pp 23–35
Voisin PJ, Rousselle D, Streiff F, Debry G, Stoltz J-F, Drouin P (1983) Reduction of β-thromboglobulin levels in diabetics controlled by artificial pancreas. Metabolism 32:138–141
WHO Study Group (1985) Diabetes mellitus. Technical Report Series 727. WHO, Geneva
Ylikorkala O, Kaila J, Viinikka L (1981) Prostacyclin and thromboxane in diabetes. Br Med J 283:1148–1150
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Landgraf-Leurs, M.M.C., Ladik, T., Smolka, B. et al. Increased thromboplastic potential in diabetes: a multifactorial phenomenon. Klin Wochenschr 65, 600–606 (1987). https://doi.org/10.1007/BF01726667
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01726667